Accumulating data from clinical practice hint that an alternative class of biologic agent may be the best choice when anti-TNF therapy for rheumatoid arthritis fails to produce the desired effect. Furthermore, evidence suggests that non-anti-TNF biologic agents should perhaps also be considered as the initial choice of biologic agent.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Yazici, Y. Treatment of rheumatoid arthritis: we are getting there. Lancet 374, 178–180 (2009).
Grigor, C. et al. Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomized controlled trial. Lancet 364, 263–269 (2004).
Goekoop-Ruiterman, Y. P. et al. Comparison of treatment strategies in early rheumatoid arthritis: a randomized trial. Ann. Intern. Med. 146, 406–415 (2007).
Möttönen, T. et al. Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo Trial Group. Lancet 353, 1568–1573 (1999).
Yazici, Y. et al. Changing patterns of tumor necrosis factor inhibitor use in 9,074 patients with rheumatoid arthritis. J. Rheumatol. 36, 907–913 (2009).
Soliman, M. M. et al. Rituximab or a second anti-TNF therapy for rheumatoid arthritis patients who have failed their first anti-TNF? Comparative analysis from the British Society for Rheumatology Biologics Register. Arthritis Care Res. (Hoboken) http://dx.doi.org/10.1002/acr.21663.
Martin-du-Pan Prujim, S. et al. Comparison of drug retention between new biological agents and classic anti-TNF agents in TNF inadequate responder rheumatoid arthritis patients [abstract #SAT0298]. Ann. Rheum. Dis. 70 (Suppl. 3), 619 (2011).
Cimmino, M. A. et al. Assessing the cost-effectiveness of biologic agents for the management of moderate-to-severe rheumatoid arthritis in anti-TNF inadequate responders in Italy: a modelling approach. Clin. Exp. Rheumatol. 29, 633–641 (2011).
Yazici, Y. & Yazici, H. Tumor necrosis factor α inhibitors, methotrexate or both? An inquiry into the formal evidence for when they are to be used in rheumatoid arthritis. Clin. Exp. Rheumatol. 26, 449–52 (2008).
Singh, J. A. et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 64, 625–639 (2012).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
Y. Yazici has acted as a consultant for, and has received research/grant support from, Abbott, Bristol-Myers Squibb, Centocor, Genentech and Pfizer, and has acted as a consultant for UCB.
Rights and permissions
About this article
Cite this article
Yazici, Y. Evidence-based rather than habit-based treatment options. Nat Rev Rheumatol 8, 374–376 (2012). https://doi.org/10.1038/nrrheum.2012.79
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrrheum.2012.79
